Visual Function with Mac-Tel Type 2 Treatment

Roger A. Goldberg, MD, MBA

Show Description +

Dr. Goldberg explores the pooled visual function data for the neurotrophic factor-producing revakinagene taroretcel (Neurotech) in patients with macular telangiectasia type 2.

Posted: 10/22/2024

Keywords:

neurotrophic factor

•

Neurotech

•

retina-meeting-recap

•

revakinagene taroretcel

•

macular telangiectasia

•

Macula

•

visual function

Up Next

Name: Visual Function with Mac-Tel Type 2 Treatment
Uploaded: 2024-10-22T20:25:25+00:00
Description: Dr. Goldberg explores the pooled visual function data for the neurotrophic factor-producing revakinagene taroretcel (Neurotech) in patients with macular telangiectasia type 2.

The Risk of PVR Revealed

Mathew W. MacCumber, MD, PHD

A Novel Scleral Buckling Technique

Maria H. Berrocal, MD

The Challenges of Epiretinal Membrane Surgery

Yasha S. Modi, MD

The 2024 Charles L Schepens MD Lecture

Steve Charles, MD, FACS, FICS

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Managing Elderly Patients With Advanced, Progressive Disease

Jody Piltz-Seymour, MD

Home Testing Ready for Prime Time?

Rachel G. Simpson, MD

Association Between GLP-1 Receptor Agonists Exposure and IOP Change

Qi N. Cui, MD, PhD

Expanding Adjustable IOL Technology

Mitchell Weikert, MD

Presbyopia-Correcting IOLs: New Categories?

Daniel H. Chang, MD

$Lenticule Extraction and Corneal Refractive Surgery$

Lenticule Extraction and Corneal Refractive Surgery

Audrey Talley Rostov, MD

Genetic Testing for Primary Open-Angle Glaucoma

Anthony P. Khawaja, MBBS

Glaucoma Lasers: What’s New?

Sarah Van Tassel, MD

Visual Field Progression in the LiGHT Trial

Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth

$Intense Pulsed Light Therapy and Refractive Surgery$

Intense Pulsed Light Therapy and Refractive Surgery

Jorge Alio Del Barrio, MD, PhD

$Frequency and Risk Factors for Ocular Pain After Refractive Surgery$

Frequency and Risk Factors for Ocular Pain After Refractive Surgery

Jason Betz, BS

Digital Imaging and Software Revolution in Ophthalmology

Cathleen McCabe, MD

Sequential CAIRS and Combined Wavefront-Guided PRK and CXL

Shady T. Awwad, MD

Causes and Prevention of TASS During Anterior Segment Surgery

Nick Mamalis, MD

Technology-Driven Tools for Improving Patient Care and Physician Wellness

Renee Bovelle, MD

36 Months of GA Therapy with Pegcetacoplan

Dilsher S. Dhoot, MD

A Look at Topline Data: EYP-1901

Carl D. Regillo, MD

Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD

Extension Data for High-Dose Aflibercept

Diana Do, MD

The Promise of a Wnt Agonist

Charles C. Wykoff, MD, PhD

Back to All Videos

Visual Function with Mac-Tel Type 2 Treatment

Roger A. Goldberg, MD, MBA

Dr. Goldberg explores the pooled visual function data for the neurotrophic factor-producing revakinagene taroretcel (Neurotech) in patients with macular telangiectasia type 2.

Posted: 10/22/2024

Keywords:

neurotrophic factor

•

Neurotech

•

retina-meeting-recap

•

revakinagene taroretcel

•

macular telangiectasia

•

Macula

•

visual function

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

Visual Function with Mac-Tel Type 2 Treatment

Up Next

Visual Function with Mac-Tel Type 2 Treatment

More From AAO: 2024 Coverage